The FDA removed Lillys tirzepatide from the drug shortage list in December 2024 and Novos semaglutide in February this year
Lin TK, Lin KJ, Lin HY, et al
This program was established to test how a category of drugs for weight management becoming available under Medicare might impact beneficiaries and the Medicare program
Individuals under 18 years of age Pregnant or breastfeeding women Individuals with medical conditions (unless approved by a healthcare professional) Anyone advised against metabolic-active compounds Generally well tolerated, but may include: Mild skin irritation Headache Nausea Changes in energy levels Users may experience improved metabolism, increased energy, and gradual improvements in body composition with consistent use
The most common type of gallbladder disease is cholecystitis, which is when theres inflammation in the gallbladder that disrupts how it functions and leads to disruptive symptoms
If you are interested in retatrutide as a potential treatment option, the most appropriate first step is to have an open and informed conversation with your GP or a specialist in obesity medicine or endocrinology